MA24682A1 - Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant - Google Patents

Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant

Info

Publication number
MA24682A1
MA24682A1 MA25309A MA25309A MA24682A1 MA 24682 A1 MA24682 A1 MA 24682A1 MA 25309 A MA25309 A MA 25309A MA 25309 A MA25309 A MA 25309A MA 24682 A1 MA24682 A1 MA 24682A1
Authority
MA
Morocco
Prior art keywords
preparation
compositions containing
polymorphic forms
cipamfylline
new polymorphic
Prior art date
Application number
MA25309A
Other languages
English (en)
Inventor
Eggleston Drake
Robert Lynch Ian
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp
Publication of MA24682A1 publication Critical patent/MA24682A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'INVENTION CONCERNE DES FORMES POLYMORPHES CRISTALLINES NOUVELLES DE 1, 3 - DICYCLOPROPYLMÉTHYL - 8 - AMINO - XANTHINE. ELLE CONCERNE ÉGALEMENT DES PROCÉDÉS POUR LEUR PRÉPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSÉS ET COMPOSITIONS DANS LE TRAITEMENT DE MALADIES à MÉDIATION PAR LA PDE4 OU LE TNF CHAE UN MAMMIFèRE.
MA25309A 1997-10-23 1998-10-21 Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant MA24682A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23

Publications (1)

Publication Number Publication Date
MA24682A1 true MA24682A1 (fr) 1999-07-01

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25309A MA24682A1 (fr) 1997-10-23 1998-10-21 Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant

Country Status (28)

Country Link
US (2) US6583283B1 (fr)
EP (1) EP1025103A4 (fr)
JP (1) JP2001520228A (fr)
KR (1) KR20010031246A (fr)
CN (1) CN1280579A (fr)
AP (1) AP2000001793A0 (fr)
AR (1) AR015190A1 (fr)
AU (1) AU751561B2 (fr)
BG (1) BG104368A (fr)
BR (1) BR9814099A (fr)
CA (1) CA2306980A1 (fr)
CO (1) CO4990930A1 (fr)
DZ (1) DZ2629A1 (fr)
EA (1) EA003445B1 (fr)
HU (1) HUP0100019A3 (fr)
ID (1) ID23885A (fr)
IL (1) IL135711A0 (fr)
MA (1) MA24682A1 (fr)
NO (1) NO20002012L (fr)
NZ (1) NZ504051A (fr)
PE (1) PE122599A1 (fr)
PL (1) PL340257A1 (fr)
SA (1) SA99191117A (fr)
SK (1) SK5642000A3 (fr)
TR (1) TR200001109T2 (fr)
UY (2) UY25220A1 (fr)
WO (1) WO1999020625A1 (fr)
ZA (1) ZA989622B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520386A (ja) 2001-01-31 2004-07-08 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なニコチンアミドビアリール誘導体
PL364910A1 (en) 2001-01-31 2004-12-27 Pfizer Products Inc. Ether derivatives useful as inhibitors of pde4 isozymes
HUP0401305A2 (hu) 2001-01-31 2004-10-28 Pfizer Products Inc. Tiazolil-, oxazolil-, pirrolil- és imidazolil-savamid-származékok, mint PDE4 izozimek inhibitorai és az ezeket tartalmazó gyógyszerkészítmények
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
DE60319980T2 (de) * 2002-05-31 2009-04-16 Schering Corporation Xanthin-phosphodiesterase-v-hemmer polymorphe
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
JP2008512380A (ja) 2004-09-03 2008-04-24 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤
US7435818B2 (en) * 2005-09-20 2008-10-14 Scinopharm Taiwan, Ltd. Crystal forms of irinotecan hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020959D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
UY25380A1 (es) 1999-11-17
CO4990930A1 (es) 2000-12-26
IL135711A0 (en) 2001-05-20
SA99191117A (ar) 2005-12-03
PE122599A1 (es) 2000-02-12
TR200001109T2 (tr) 2000-09-21
UY25220A1 (es) 2001-08-27
CN1280579A (zh) 2001-01-17
EP1025103A1 (fr) 2000-08-09
AU1274499A (en) 1999-05-10
ID23885A (id) 2000-05-25
CA2306980A1 (fr) 1999-04-29
NO20002012D0 (no) 2000-04-17
EA003445B1 (ru) 2003-06-26
AP2000001793A0 (en) 2000-06-30
WO1999020625A1 (fr) 1999-04-29
HUP0100019A3 (en) 2003-01-28
AR015190A1 (es) 2001-04-18
JP2001520228A (ja) 2001-10-30
US20020173648A1 (en) 2002-11-21
PL340257A1 (en) 2001-01-29
KR20010031246A (ko) 2001-04-16
NO20002012L (no) 2000-04-17
AU751561B2 (en) 2002-08-22
EP1025103A4 (fr) 2001-11-14
BG104368A (en) 2001-02-28
ZA989622B (en) 1999-04-23
SK5642000A3 (en) 2000-09-12
BR9814099A (pt) 2000-10-10
DZ2629A1 (fr) 2003-03-08
NZ504051A (en) 2003-02-28
HUP0100019A2 (hu) 2002-01-28
US6583283B1 (en) 2003-06-24
EA200000448A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
MA26723A1 (fr) Acides oxamiques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26729A1 (fr) Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98025A1 (fr) Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant.
DZ2186A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de l'ostéoporose et procédé pour leur préparation.
MA25035A1 (fr) Derives de 3-azabicyclo [3,1,0] hexane nouveaux, procede pour leur preparation et compositions les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98112A1 (fr) Composes dipeptidiques
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
DZ2639A1 (fr) Composés thérapeutiquement actifs basés sur le remplacement bio-isostérique du catéchol par l'indazole dans des inhibiteurs de PDE4 leur procédé de production et compositions pharmaceutiques les contenant.
MA26700A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc à LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION.
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98035A1 (fr) Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26739A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques les contenant
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26608A1 (fr) Procede de preparation d'une composition pharmaceutique destinee au traitement de l'insuffisance cardiaque.
TNSN96153A1 (fr) Procedes et intermediaires pour la preparation de 1-benzyl-4 ((5,6 -dimethoxy-1-indanone)-2- yl) methylpiperidine.
MA26741A1 (fr) Suspensions de ziprasidone nouvelles et procede pour leur preparation.
MA24682A1 (fr) Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
MA24685A1 (fr) Derives d'erythromycine tricycliques nouveaux, procede pour leur preparation et composition les contenant